3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 2/3
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Wilms Tumor
1
Uveal Melanoma
1
Thyroid Cancer, Papillary
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Medulloblastoma
1
Glioma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
26
Bevacizumab
14
Radiosurgery
12
Radiotherapy
9
pembrolizumab
8
Carboplatin
8
Trastuzumab
6
temsirolimus
5
Sirolimus
5
Erlotinib Hydrochloride
5
abemaciclib
4
Paclitaxel
4
Irinotecan
4
Capecitabine
4
tipifarnib
3
Sorafenib
3
Radiation
3
Mental Status and Dementia Tests
3
Ipilimumab
3
Everolimus
3
Aminolevulinic Acid
3
130-nm albumin-bound paclitaxel
3
tucatinib
2
pertuzumab
2
fludarabine
2
durvalumab
2
alovudine
2
alectinib
2
Vorinostat
2
Surgical Procedures, Operative
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Brain Neoplasms
×
entrectinib
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA